IRIS
AMODIO, Nicola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.298
AS - Asia 1.266
EU - Europa 1.078
SA - Sud America 94
Continente sconosciuto - Info sul continente non disponibili 16
AF - Africa 15
OC - Oceania 2
Totale 4.769
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.231
SG - Singapore 884
IT - Italia 557
CN - Cina 259
SE - Svezia 193
GB - Regno Unito 99
BR - Brasile 83
DE - Germania 74
CA - Canada 59
IN - India 35
FI - Finlandia 33
RO - Romania 26
BD - Bangladesh 15
EU - Europa 15
CZ - Repubblica Ceca 13
HK - Hong Kong 13
NL - Olanda 13
FR - Francia 10
PL - Polonia 10
IR - Iran 9
JP - Giappone 9
RU - Federazione Russa 9
UA - Ucraina 9
EG - Egitto 8
MX - Messico 8
AT - Austria 6
CH - Svizzera 5
ES - Italia 5
GR - Grecia 5
TR - Turchia 5
YE - Yemen 5
CL - Cile 4
PK - Pakistan 4
VN - Vietnam 4
ZA - Sudafrica 4
AE - Emirati Arabi Uniti 3
EE - Estonia 3
IQ - Iraq 3
MY - Malesia 3
SA - Arabia Saudita 3
AU - Australia 2
DK - Danimarca 2
EC - Ecuador 2
IL - Israele 2
LT - Lituania 2
UZ - Uzbekistan 2
VE - Venezuela 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AR - Argentina 1
BO - Bolivia 1
GE - Georgia 1
JO - Giordania 1
KE - Kenya 1
KW - Kuwait 1
LB - Libano 1
MK - Macedonia 1
NO - Norvegia 1
NP - Nepal 1
PH - Filippine 1
PT - Portogallo 1
RS - Serbia 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
TW - Taiwan 1
UY - Uruguay 1
Totale 4.769
Salva come PNG Salva come JPEG
Città #
Singapore 422
Chandler 388
Santa Clara 227
Lawrence 189
Princeton 189
Milan 188
Catanzaro 134
Wilmington 106
Chicago 85
London 84
Beijing 72
Ashburn 59
Des Moines 57
Munich 51
Ottawa 47
Turku 29
Shanghai 24
Boardman 23
Redwood City 20
Los Angeles 18
Guangzhou 16
Horia 14
San Francisco 14
The Dalles 14
Hong Kong 13
Norwalk 13
Pune 13
Olomouc 12
Brooklyn 11
Rome 11
Hanover 10
Redmond 10
Timisoara 10
Cosenza 9
Naples 9
New York 9
São Paulo 9
Warsaw 9
Bari 8
Ann Arbor 7
Jiaxing 7
Lamezia Terme 7
San Jose 7
San Nicola Manfredi 7
Settingiano 7
Shenzhen 7
Boston 6
Hefei 6
Mexico City 6
Palermo 6
Parma 6
Reggio Calabria 6
West Jordan 6
Andover 5
Augusta 5
Aversa 5
Charlotte 5
Dhaka 5
Nanjing 5
Phoenix 5
Sanaa 5
Atlanta 4
Caserta 4
Chennai 4
Council Bluffs 4
Hebei 4
Helsinki 4
Novokuznetsk 4
Stockholm 4
Taranto 4
Toronto 4
Xi'an 4
Ahmedabad 3
Cetraro 3
Fayetteville 3
Hanoi 3
Johannesburg 3
Masera 3
Montreal 3
Napoli 3
Raleigh 3
San Mateo 3
Treviso 3
Vienna 3
Zhengzhou 3
6th of October City 2
Amsterdam 2
Ankara 2
Apo 2
Assago 2
Basti 2
Benevento 2
Blumenau 2
Brugnera 2
Cairo 2
Canoas 2
Ceglie Del Campo 2
Columbus 2
Diemen 2
Duhok 2
Totale 2.870
Salva come PNG Salva come JPEG
Nome #
miR-22 suppresses DNA ligase III addiction in multiple myeloma 84
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells 62
A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine. 62
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells in vitro 56
LNA-Gapmer Antisense Oligonucleotides Targeting the Oncogenic Lncrna MALAT1 Trigger Anti-Multiple Myeloma Activity By Proteasome Blockade 55
Early hematopoietic zinc finger protein (EHZF), the human homolog to mouse Evi3, is highly expressed in primitive human hematopoietic cells 52
Molecular and clinical types of plasma cell dyscrasias are associated with distinct expression patterns of long noncoding RNAs 51
A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells 50
MYC-MIR-22 REGULATORY LOOP MODULATES LENALIDOMIDE ACTIVITY IN MULTIPLE MYELOMA CELLS 49
MIR-21 SUPPRESSION IMPAIRS TH17 RELATED BONE DISEASE IN MULTIPLE MYELOMA 48
IL-6 Receptor Blockade by Tocilizumab Has Anti-absence and Anti-epileptogenic Effects in the WAG/Rij Rat Model of Absence Epilepsy 48
Mitochondrial dysfunction at the crossroad of cardiovascular diseases and cancer 47
TARGETING OF DEREGULATED LNCRNA NEAT1 AFFECTS MULTIPLE MYELOMA ACTIVITY 45
Discovery, Functional Characterization and Therapeutic Targeting of Lnc-17-92 Metabolic Signaling in Multiple Myeloma 45
Bergamot Polyphenols Improve Dyslipidemia and Pathophysiological Features in a Mouse Model of Non-Alcoholic Fatty Liver Disease 45
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 45
Turning Stem Cells Bad: Generation of Clinically Relevant Models of Human Acute Myeloid Leukemia through Gene Delivery- or Genome Editing-Based Approaches 44
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. 44
ZNF423: A New Player in Estrogen Receptor-Positive Breast Cancer 42
ACTIVATION OF GPER SIGNALING AS A POTENTIAL THERAPEUTIC STRATEGY AGAINST WALDENSTROM MACROGLOBULINEMIA 42
Early hematopoietic zinc finger protein, a novel transcription co-factor with a potential role in haematopoietic homeostasis and leukaemogenesis 41
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma 40
Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation 40
Impact of natural dietary agents on multiple myeloma prevention and treatment: molecular insights and potential for clinical translation. 40
Early Hematopoietic Zinc Finger protein (EHZF), the human homologue to Evi3, is highly expressed in primitive human hematopoietic cells 40
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 40
Effects of Histone Deacetylase Inhibitors on the Development of Epilepsy and Psychiatric Comorbidity in WAG/Rij Rats 40
P21-ACTIVATED KINASE 4 (PAK4) REGULATES MULTIPLE MYELOMA (MM) CELL GROWTH AND SURVIVAL BY MODULATION OF CRITICAL TRANSCRIPTIONAL PATHWAYS: THERAPEUTIC APPLICATION OF PAK4 ALLOSTERIC INHIBITORS 39
Cateslytin abrogates lipopolysaccharide-induced cardiomyocyte injury by reducing inflammation and oxidative stress through toll like receptor 4 interaction 39
Radiation induced by-stander effect: possible RNA implication in DNA damage transmission? 38
ZNF423: A New Player in Estrogen Receptor-Positive Breast Cancer. 38
Synthesis and preliminary evaluation of the anti-cancer activity on A549 lung cancer cells of a series of unsaturated disulfides. 37
Anti-MALAT1 synthetic oligonucleotides target the proteasome and exert anti-multiple myeloma activity 37
Inhibitor of DNA binding 2 (ID2) regulates key transcriptional programs in multiple myeloma 37
In Vitro Silencing of lncRNAs Using LNA GapmeRs 36
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. 35
Ex-vivo characterization of circulating colon cancer cells distinguished in stem and differentiated subset provides useful biomarker for personalized metastatic risk assessment 35
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells 35
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. 34
Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation 34
Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma 34
Activation of the Non-Canonical Estrogen Receptor Gper As a Novel Therapeutic Strategy Against Waldenstrom Macroglobulinemia 34
Contribution of PKB/AKT signaling to thyroid cancer 34
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 34
A MIR17HG-derived Long Noncoding RNA Provides an Essential Chromatin Scaffold for Protein Interaction and Myeloma Growth 33
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma 33
In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma 33
A 13 mer LNA miR-221 inhibitor restores drug sensitivity in melphalan-refractory multiple myeloma cells 33
CRISPR Interference (CRISPRi) and CRISPR Activation (CRISPRa) to Explore the Oncogenic lncRNA Network 33
Znf521 enhances mll‐af9‐dependent hematopoietic stem cell transformation in acute myeloid leukemias by altering the gene expression landscape† 32
MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment 31
Alternative non-homologous end joining DNA repair as therapeutic target in multiple myeloma 31
In vitro and vivo activity against multiple myeloma cells of a novel locked nucleic acid (LNA)-miR-221 inhibitor 31
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells 31
MiR-34a Replacement As a Novel Therapeutic Approach for Multiple Myeloma: Preclinical In Vitro and In Vivo Evidence 31
Early hematopoietic zinc finger protein prevents tumor cell recognition by natural killer cells 31
Early hematopoietic zinc finger protein - zinc finger protein 521 (EHZF/ZNF521): a candidate regulator of diverse immature cells 30
In vitro expansion of tumour cells derived from blood and tumour tissue is useful to redefine personalized treatment in non-small cell lung cancer patients 30
Oleil hydroxytyrosol (Htol) exerts anti-myeloma activity by antagonizing key survival pathways in malignant plasma cells 30
Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth 29
From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario 29
Biological Insights into Myeloma and Other B Cell Malignancies 29
Early Hematopoietic Zinc Finger (EHZF/ZNF521) prevents tumor cell recognition by Natural Killer Cells 28
Mouse Models as a Translational Platform for the Development of New Therapeutic Agents in Multiple Myeloma 27
Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma 27
Activating E17K mutation in the gene encoding the protein kinase B/AKT in squamous cell carcinoma of the lung 27
The non-coding RNA landscape of plasma cell dyscrasias 27
Mitochondrial Determinants of Anti-Cancer Drug-Induced Cardiotoxicity 26
A Comparison of Different Sample Processing Protocols for MALDI Imaging Mass Spectrometry Analysis of Formalin-Fixed Multiple Myeloma Cells 26
A Comparison of Different Sample Processing Protocols for MALDI Imaging Mass Spectrometry Analysis of Formalin-Fixed Multiple Myeloma Cells 26
Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia 26
Disentangling the microRNA regulatory milieu in multiple myeloma: integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients 26
Functional Analysis of microRNA in Multiple Myeloma 25
SI113, a SGK1 inhibitor, potentiates the effects of radiotherapy, modulates the response to oxidative stress and induces cytotoxic autophagy in human glioblastoma multiforme cells. 25
Non-coding RNA: A novel opportunity for the personalized treatment of multiple myeloma 25
Arginine Methylation Mediated By PRMT5 Has Significant Biological and Clinical Impact in Multiple Myeloma 25
Receptor identification and physiological characterisation of glucagon-like peptide-2 in the rat heart 25
The chromogranin A1-373 fragment reveals how a single change in the protein sequence exerts strong cardioregulatory effects by engaging neuropilin-1 25
Chromofungin, CgA47-66-derived peptide, produces basal cardiac effects and postconditioning cardioprotective action during ischemia/reperfusion injury 25
Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma. 24
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity 24
Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment. 23
Zinc finger protein 521 antagonizes early B-cell factor 1 and modulates the B-lymphoid differentiation of primary hematopoietic progenitors 23
Circulating biomarkers in osteosarcoma: new translational tools for diagnosis and treatment. 23
Contribution of PKB/AKT signaling to thyroid cancer 22
miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies 22
Selective G-Protein Estrogen Receptor (GPER) Activation Triggers Anti-Multiple Myeloma Activity and Synergizes with MiR-29b-Inducing Drugs 22
Early Hematopoietic Zinc Finger protein (EHZF), a novel co-transcription factor: functional properties, expression in myelogenous leukaemias and interactions with histone deacetylases 22
Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma 22
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 22
Current status and future perspectives on therapeutic potential of apigenin: Focus on metabolic-syndrome-dependent organ dysfunction 22
In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor 21
miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1 21
Selective Activation of the Non-Classical Estrogen Receptor Gper Elicits Potent Anti-Tumor Activity in Multiple Myeloma 21
Challenges in multiple myeloma chemoprevention: potential role of natural, synthetic and endogenous molecules 21
DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma 20
Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma 20
miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth 20
Early hematopoietic zinc finger (EHZF), a multifunctional transcription co-factor expressed in human early hematopoietic cells and AML blasts 20
MiR-29b Exerts Anti-Multiple Myeloma Activity by Targeting Key Oncogenic Pathways and Modulating DNA Methylation Profile 20
Totale 3.363
Salva come PNG Salva come JPEG
Categoria #
all - tutte 78.140
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 78.140
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021337 19 3 14 14 34 21 20 14 54 45 72 27
2021/2022569 23 2 5 154 38 13 24 113 54 61 71 11
2022/20231.183 386 64 71 68 100 93 5 87 163 51 70 25
2023/2024515 113 73 34 42 28 129 13 8 2 14 19 40
2024/20252.129 321 95 65 58 151 302 44 51 266 130 214 432
2025/202623 23 0 0 0 0 0 0 0 0 0 0 0
Totale 4.999